, Volume 65, Issue 1, pp 75–87 | Cite as


A Resurgent Antimalarial Drug
  • Timothy M. E. Davis
  • Te-Yu Hung
  • Ing-Kye Sim
  • Harin A. Karunajeewa
  • Kenneth F. Ilett
Review Article


Piperaquine is a bisquinoline antimalarial drug that was first synthesised in the 1960s, and used extensively in China and Indochina as prophylaxis and treatment during the next 20 years. A number of Chinese research groups documented that it was at least as effective as, and better tolerated than, chloroquine against falciparum and vivax malaria, but no pharmacokinetic characterisation was undertaken. With the development of piperaquine-resistant strains of Plasmodium falciparum and the emergence of the artemisinin derivatives, its use declined during the 1980s.

However, during the next decade, piperaquine was rediscovered by Chinese scientists as one of a number of compounds suitable for combination with an artemisinin derivative. The rationale for such artemisinin combination therapies (ACTs) was to provide an inexpensive, short-course treatment regimen with a high cure rate and good tolerability that would reduce transmission and protect against the development of parasite resistance. This approach has now been endorsed by the WHO.

Piperaquine-based ACT began as China-Vietnam 4 (CV4®: dihydroartemisinin [DHA], trimethoprim, piperaquine phosphate and primaquine phosphate), which was followed by CV8® (the same components as CV4 but in increased quantities), Artecom® (in which primaquine was omitted) and Artekin® or Duo-Cotecxin® (DHA and piperaquine phosphate only). Recent Indochinese studies have confirmed the excellent clinical efficacy of piperaquine-DHA combinations (28-day cure rates >95%), and have demonstrated that currently recommended regimens are not associated with significant cardiotoxicity or other adverse effects.

The pharmacokinetic properties of piperaquine have also been characterised recently, revealing that it is a highly lipid-soluble drug with a large volume of distribution at steady state/bioavailability, long elimination half-life and a clearance that is markedly higher in children than in adults. The tolerability, efficacy, pharmacokinetic profile and low cost of piperaquine make it a promising partner drug for use as part of an ACT.


  1. 1.
    Chen L, Qu FY, Zhou YC. Field observations on the anti-malarial piperaquine. Chin Med J 1982; 95: 281–6PubMedGoogle Scholar
  2. 2.
    Hien TT, Dolecek C, Mai PP, et al. Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet 2004; 363: 18–22CrossRefGoogle Scholar
  3. 3.
    World Health Organization. Antimalarial drug combination therapy. Report of a technical consultation. Geneva: World Health Organization, 2001 Apr 4–5. WHO/CDS/RBM/2001Google Scholar
  4. 4.
    Tip NQ, Trung TN, Tan TV, et al. A field trial for efficacy of CV8 in treatment of uncomplicated falciparum malaria. J Malaria Parasit Dis Cont 2001, 45–51Google Scholar
  5. 5.
    Tien NT, Uyen TT, Huong DX, et al. Efficacy of CV8 for treatment of drug-resistant falciparum malaria. J Malaria Parasit Dis Cont 2002, 37–40Google Scholar
  6. 6.
    Verle P, Nhan DH, Tinh TT, et al. Glucose-6-phosphate dehy-drogenase deficiency in northern Vietnam. Trop Med Int Health 2000; 5: 203–6PubMedCrossRefGoogle Scholar
  7. 7.
    Wilairatana P, Krudsood S, Chalermrut K, et al. An open randomized clinical trial of Artecom vs artesunate-mefloquine in the treatment of acute uncomplicated falciparum malaria in Thailand. SE Asian J Trop Med Publ Hlth 2002; 33: 519–24Google Scholar
  8. 8.
    Denis MB, Davis TME, Hewitt S, et al. Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. Clin Infect Dis 2002; 35: 1469–76PubMedCrossRefGoogle Scholar
  9. 9.
    Hung TY, Davis TM, Ilett KF. Measurement of piperaquine in plasma by liquid chromatography with ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 791: 93–101PubMedCrossRefGoogle Scholar
  10. 10.
    Sunderland B, Passmore P, Boddy M. Working paper: assay of antimalarial drugs in combination formulations. In: Meeting on antimalarial drug development; 2001 Nov 16–17; Shanghai, China: World Health Organization Regional Office For the Western Pacific. Manila: World Health Organization, 2002: 41–52Google Scholar
  11. 11.
    Piperaquine. SciFinder Scholar. Columbus (OH): American Chemical Society, 2004Google Scholar
  12. 12.
    Hung TY. Pharmacokinetics of piperaquine in humans [B Med Sci Thesis]. Crawley (WA): University of Western Australia, 2002Google Scholar
  13. 13.
    The State Pharmacopoeia Commission of The People’s Republic of China. Pharmacopoeia of the People’s Republic of China. Beijing: Chemical Industry Press, 2000Google Scholar
  14. 14.
    Xu D, Shen N, Li Y, et al. Studies on the antimalarial drug hydroxypiperaquine and its phosphate. J Med Coll PLA 1988; 3: 5–12Google Scholar
  15. 15.
    Li J, Huang W. Effects of artesunate, pyronaridine, and hydroxypiperaquine on chloroquine-sensitive and chloroquine-resistant isolates of Plasmodium falciparum in vitro [in Chinese]. Zhongguo Yao Li Xue Bao 1988; 9: 83–6PubMedGoogle Scholar
  16. 16.
    Chen L. Recent studies on antimalarial efficacy of piperaquine and hydroxypiperaquine. Chin Med J 1991; 104: 161–3PubMedGoogle Scholar
  17. 17.
    Xu D, Shen N, Yin M, et al. New antimalarial and antisilicosis drug hydroxypiperaquine [in Chinese]. Zhongguo Yiyao Gongye Za Zhi 1989; 20: 488–93Google Scholar
  18. 18.
    Li Y, Hu Y, Huang H. Hydroxypiperaquine phosphate in treatment of falciparum malaria. Chin Med J 1981; 94: 301–2PubMedGoogle Scholar
  19. 19.
    Raynes K. Bisquinoline antimalarials: their role in malaria chemotherapy. Int J Parasitol 1999; 29: 367–79PubMedCrossRefGoogle Scholar
  20. 20.
    Raynes K, Foley M, Tilley L, et al. Novel bisquinoline antimalarials: synthesis, antimalarial activity, and inhibition of haem polymerisation. Biochem Pharmacol 1996; 52: 551–9PubMedCrossRefGoogle Scholar
  21. 21.
    Vennerstrom JL, Ellis WY, Ager Jr AL, et al. Bisquinolines: 1. N,N-bis(7-chloroquinolin-4-yl)alkanediamines with potential against chloroquine-resistant malaria. J Med Chem 1992; 35: 2129–34PubMedCrossRefGoogle Scholar
  22. 22.
    O’Neill PM, Bray PG, Hawley SR, et al. 4-Aminoquinolines —past, present, and future: a chemical perspective. Pharmacol Ther 1998; 77: 29–58PubMedCrossRefGoogle Scholar
  23. 23.
    Jain R. Recent advancements in antimalarial drug development. Curr Res Inf Pharm Sci 2002; 3: 2–8Google Scholar
  24. 24.
    Chen L, Qian YL, Li ZL, et al. Effects of piperaquine on the fine structure of the erythrocytic stages of Plasmodium berghei ANKA strain. Zhongguo Yao Li Xue Bao 1986; 7: 351–3PubMedGoogle Scholar
  25. 25.
    Chen L, Dai ZR, Qian YL, et al. The fine structure of the blood stages of the piperaquine-resistant line of Plasmodium berghei ANKA strain. Chin J Parasitol Parasit Dis 1985; 3: 281–3Google Scholar
  26. 26.
    Chen PQ, Chen L, Li GQ, et al. Effects of new antimalarial drugs in combination, Artekin, on ultrastructure of erythrocytic stages of Plasmodium berghei ANKA strain. Chin Med J 2002; 115: 129–31Google Scholar
  27. 27.
    Hempelmann E, Motta C, Hughes R, et al. Plasmodium falci-parum: sacrificing membrane to grow crystals? Trends Parasitol 2003; 19: 23–6PubMedCrossRefGoogle Scholar
  28. 28.
    Sullivan Jr DJ, Gluzman IY, Russell DG, et al. On the molecular mechanism of chloroquine’s antimalarial action. Proc Natl Acad Sci U S A 1996; 93: 11865–70PubMedCrossRefGoogle Scholar
  29. 29.
    Sullivan DJ. Theories on malarial pigment formation and quinoline action. Int J Parasitol 2002; 32: 1645–53PubMedCrossRefGoogle Scholar
  30. 30.
    Ginsburg H, Famin O, Zhang J, et al. Inhibition of glutathione-dependent degradation of heme by chloroquine and amodia-quine as a possible basis for their antimalarial mode of action. Biochem Pharmacol 1998; 56: 1305–13PubMedCrossRefGoogle Scholar
  31. 31.
    Guan WB, Huang WJ, Zhou YC, et al. Effect of piperaquine and hydroxypiperaquine on a chloroquine-resistant strain of Plasmodium falciparum. Chin J Parasitol Parasit Dis 1983; 1: 88–90Google Scholar
  32. 32.
    Deloron P, LeBras J, Ramanamirija JA, et al. Plasmodium falciparum in Madagascar: in vivo and in vitro sensitivity to seven drugs. Ann Trop Med Parasitol 1985; 79: 357–65PubMedGoogle Scholar
  33. 33.
    Yang H, Liu D, Huang K, et al. Assay of sensitivity of Plasmodium falciparum to chloroquine, amodiaquine, piperaquine, mefloquine and quinine in Yunnan province. Chin J Parasitol Parasit Dis 1999; 17: 43–5Google Scholar
  34. 34.
    Fan B, Zhao W, Ma X, et al. In vitro sensitivity of Plasmodium falciparum to chloroquine, piperaquine, pyronaridine and artesunate in Yuxi prefecture of Yunnan province. Chin J Parasitol Parasit Dis 1998; 16: 460–2Google Scholar
  35. 35.
    Yang H, Liu D, Dong Y, et al. Sensitivity of Plasmodium falciparum to seven antimalarials in China-Laos border. Chin J Parasitol Parasit Dis 1995; 13: 111–3Google Scholar
  36. 36.
    Yang HL, Yang PF, Liu DQ, et al. Sensitivity in vitro of Plasmodium falciparum to chloroquine, pyronaridine, artesunate and piperaquine in south Yunnan. Chin J Parasitol Parasit Dis 1992; 10: 198–200Google Scholar
  37. 37.
    Zhang KY, Zhou JX, Wu Z, et al. Susceptibility of Plasmodium falciparum to chloroquine, piperaquine, amodiaquine, mefloquine and quinine with in vitro microtechnique in Hainan Island. Chin J Parasitol Parasit Dis 1987; 5: 165–9Google Scholar
  38. 38.
    Coulanges P, Le Bras J, Deloron P, et al. In vivo and in vitro study of the chemosensitivity of Plasmodium falciparum in Madagascar: 1982–1986. Arch Inst Pasteur Madagascar 1987; 53: 63–76PubMedGoogle Scholar
  39. 39.
    Basco LK, Ringwald P. In vitro activities of piperaquine and other 4-aminoquinolines against clinical isolates of Plasmodium falciparum in Cameroon. Antimicrob Agents Chemother 2003; 47: 1391–4PubMedCrossRefGoogle Scholar
  40. 40.
    Li GD, Qu FY, Chen L. Development of piperaquine-resistant line of Plasmodium berghei ANKA strain. Chin J Parasitol Parasit Dis 1985; 3: 189–92Google Scholar
  41. 41.
    Li GD. Development of a piperaquine-resistant line of Plasmodium berghei K 173 strain. Yao Xue Xue Bao 1985; 20: 412–7PubMedGoogle Scholar
  42. 42.
    Qu F, Li CJ, Wang NJ. Prophylactic and therapeutic effects of piperaquine and its compounds on Plasmodium berghei. Pharm Ind 1981; 1: 219–21Google Scholar
  43. 43.
    Chawira AN, Warhurst DC. The effect of artemisinin combined with standard antimalarials against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro. J Trop Med Hyg 1987; 90: 1–8PubMedGoogle Scholar
  44. 44.
    Zhu DQ, Dai ZR, Li JC. Long-acting antimalarials: piperaquine in the prophylactic therapeutic study of rodent malaria. Acta Pharmacol Sin 1982; 17: 894–7Google Scholar
  45. 45.
    Qu FY. The antimalarial effects of piperaquine phosphate and sulphadoxine composite as tested in Hainan Island. Zhonghua Yi Xue Za Zhi 1981; 61: 388–91PubMedGoogle Scholar
  46. 46.
    Chen L, Qu FY, Zhou YC. Field observation of prophylactic effect of the new antimalarial piperaquine in Hainan province. Med J PLA 1979; 4: 104–8Google Scholar
  47. 47.
    Qu FY, Li CJ, Chen ZD. Prophylactic efficacy on malaria of piperaquine phosphate combined with sulfadoxine. Chin Med J 1981; 61: 388–91Google Scholar
  48. 48.
    Huang JZ, Lan XH, Xu WZ. Sensitivity of Plasmodium falciparum to piperaquine in Baoting County, Hainan Island. Chin J Parasitol Parasit Dis 1985; 3: 276–7Google Scholar
  49. 49.
    Lan CX, Lin X, Huang ZS, et al. In vivo sensitivity of Plasmodium falciparum to piperaquine phosphate assayed in Linshui and Baisha counties, Hainan province. Chin J Parasitol Parasit Dis 1989; 7: 163–5Google Scholar
  50. 50.
    Chen L, Dai ZR, Qian YL, et al. Observation on the efficacy of combined use of some new antimalarials for the treatment of falciparum malaria in Hainan Province. Chin J Parasitol Parasit Dis 1989; 7: 81–4Google Scholar
  51. 51.
    Guo XB, Fu LC. Comparative study of artemisinin suppositories and piperaquine phosphate in the treatment of falciparum malaria. Zhong Xi Yi Jie He Za Zhi 1989; 9: 475–3PubMedGoogle Scholar
  52. 52.
    Guo XB. Randomised comparison on the treatment of falciparum malaria with dihydroartemisinin and piperaquine. Zhonghua Yi Xue Za Zhi 1993; 73: 602–4PubMedGoogle Scholar
  53. 53.
    Wang G. Curing 3 patients of chloroquine-resistant falciparum malaria with resistant level III by piperaquine. Chung Hua Chuan Jan Ping Tsa Chih 1985; 3: 78–80Google Scholar
  54. 54.
    World Health Organization. A brief report of piperaquine in the treatment of 280 vivax malaria patients. Geneva: World Health Organization, 1973Google Scholar
  55. 55.
    White NJ, Nosten F, Looareesuwan S, et al. Averting a malaria disaster. Lancet 1999; 353: 1965–7PubMedCrossRefGoogle Scholar
  56. 56.
    Olliaro P, Taylor WR, Rigal J. Controlling malaria: challenges and solutions. Trop Med Int Health 2001; 6: 922–7PubMedCrossRefGoogle Scholar
  57. 57.
    World Health Organization. Assessment of the safety of artemisinin compounds in pregnancy: report of two informal consultations convened by WHO in 2002 (Roll Back Malaria and the NUDP/World bank/WHO Special Programme for Research and Training in Tropical Diseases). Geneva: World Health Organization, 2003Google Scholar
  58. 58.
    Nosten F, Brasseur P. Combination therapy for malaria: the way forward? Drugs 2002; 62(9): 1315–29PubMedCrossRefGoogle Scholar
  59. 59.
    Adjuik M, Agnamey P, Babiker A, et al. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multi-centre trial. Lancet 2002; 359: 1365–72PubMedCrossRefGoogle Scholar
  60. 60.
    Duffy PE, Mutabingwa TK. Drug combinations for malaria: time to ACT? Lancet 2004; 363: 3–4PubMedCrossRefGoogle Scholar
  61. 61.
    Binh TQ, Ilett KF, Batty KT, et al. Oral bioavailability of dihydroartemisinin in Vietnamese volunteers and in patients with falciparum malaria. Br J Clin Pharmacol 2001; 51: 541–6PubMedCrossRefGoogle Scholar
  62. 62.
    Development Health Vietnam. Medicine for national malaria control project. Intellasia 2001 Apr 25 [online]. Available from URL: http://www.intellasia.com [Accessed 2002 Nov 1]
  63. 63.
    Nguyen VN, Song YZ. A summary of field study on CV8 in the treatment of 232 carriers of malaria parasite. Tonghe Pharmaceutical Co. Ltd [online]. Available from URL: http://www.artecom.com.cn/html/english/products/case/case3.htm [Accessed 2004 Jan 1]
  64. 64.
    Giao PT, de Vries PJ, Hung LQ, et al. CV8, a new combination of dihydroartemisinin, piperaquine, trimethoprim and primaquine, compared with atovaquone-proguanil against falciparum malaria in Vietnam. Trop Med Int Health 2004; 9: 209–16PubMedCrossRefGoogle Scholar
  65. 65.
    World Health Organization. Antimalarial drug combination therapy: report of a WHO technical consultation. Geneva: World Health Organization, 2001: 1–36Google Scholar
  66. 66.
    World Health Organization. Country profile: Cambodia. World Health Organization, Western Pacific Regional Office, 2002 [online]. Available from URL: http://www.wpro.who.int/malaria/themesl_focus2a.asp [Accessed 2004 Jan 1]
  67. 67.
    World Health Organization. Review of application for inclusion of a drug in the WHO essential drugs list: fixed combination of artemether and lumefantrine (COARTEM). Geneva: World Health Organization/Roll Back Malaria, 2002: 1–24Google Scholar
  68. 68.
    Karunajeewa H, Lim C, Hung T, et al. Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin®) in Cambodian children and adults with malaria. Br J Clin Pharmacol 2004; 57: 93–9PubMedCrossRefGoogle Scholar
  69. 69.
    Chen Q, Deng J, Wu D. Study on absorption, distribution and excretion of 14C-piperaquine phosphate and 14C-piperaquine in mice. Pharm Ind 1979; 8: 19–23Google Scholar
  70. 70.
    Sheng N, Jiang W, Tang HL. Pre-clinical toxical study of new antimalarial agents: II. Piperaquine phosphate and its compound ‘Preventive No.3’. Ti Erh Chun i Ta Hsueh Hsueh Pao (Acad J Second Military College) 1981; 1: 40–6Google Scholar
  71. 71.
    Hung T, Davis T, Ilett K, et al. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol 2004; 57: 253–62PubMedCrossRefGoogle Scholar
  72. 72.
    Lindegårdh N. Development of field-adapted analytical methods for the determination of new antimalarial drugs in biological fluids [PhD thesis]. Uppsala: Uppsala University, 2003: 1–64Google Scholar
  73. 73.
    Sim I-K. Pharmacokinetics of piperaquine in healthy volunteers; effects of food on bioavailability [B Med Sci thesis]. Crawley (WA): University of Western Australia, 2003Google Scholar
  74. 74.
    Lindegardh N, Ashton M, Bergqvist Y. Automated solid-phase extraction method for the determination of piperaquine in plasma by peak compression liquid chromatography. J Chromatogr Sci 2003; 41: 44–9PubMedGoogle Scholar
  75. 75.
    White NJ. Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet 1985; 10: 187–215PubMedCrossRefGoogle Scholar
  76. 76.
    Milton KA, Edwards G, Ward SA, et al. Pharmacokinetics of halofantrine in man: effects of food and dose size. Br J Clin Pharmacol 1989; 28: 71–7PubMedCrossRefGoogle Scholar
  77. 77.
    Crevoisier C, Handschin J, Barre J, et al. Food increases the bioavailability of mefloquine. Eur J Clin Pharmacol 1997; 53: 135–9PubMedCrossRefGoogle Scholar
  78. 78.
    Rolan PE, Mercer AJ, Weatherley BC, et al. Examination of some factors responsible for a food-induced increase in absorption of atovaquone. Br J Clin Pharmacol 1994; 37: 13–20PubMedCrossRefGoogle Scholar
  79. 79.
    Zhao HJ, Xia YY, Zheng Z. Pre-clinical toxical study of new antimalarial agents: IV. Liver ultrastructure changes affected by antimalarial agent, compound tablet of piperaquine phosphate and sulfadoxine. Ti Erh Chun i Ta Hsueh Hsueh Pao 1981; 1: 47–8Google Scholar
  80. 80.
    Nosten F, van Vugt M, Price R, et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 2000; 356: 297–302PubMedCrossRefGoogle Scholar
  81. 81.
    MMV partner in historic agreement to develop antimalarial drug. MMV News 2004 Apr; 7: 1–2 [online]}. Available from URL: http://www.mmv.org/FilesUpld/174.pdf [Accessed 2004 Nov 23]

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Timothy M. E. Davis
    • 1
  • Te-Yu Hung
    • 1
  • Ing-Kye Sim
    • 1
  • Harin A. Karunajeewa
    • 1
  • Kenneth F. Ilett
    • 1
  1. 1.Medicine Unit Fremantle and Pharmacology Unit Nedlands, School of Medicine and PharmacologyUniversity of Western AustraliaCrawleyAustralia
  2. 2.School of Medicine and PharmacologyUniversity of Western Australia, Fremantle HospitalFremantleAustralia

Personalised recommendations